For many large and small biopharma companies, Europe is the most important global market after the US. However, the European Union and the UK present a more complex landscape than the US in terms of languages, cultures, and diversity of regulatory and reimbursement challenges.
As a result, emerging biopharma companies hoping to establish a presence in Europe often struggle to identify the best approach.
In this article, Syneos Health experts examine a variety of go-to-market strategies, highlighting pros and cons of each, key geographic differentiators and strategic considerations for the European market, and offer insights that are not only relevant to oncology products, but can also extend to assets in a myriad of important therapeutic areas including cardiovascular, endocrine and neurology, and rare disease.
